GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies

MEMPHIS, Tenn. & SAN DIEGO–(BUSINESS WIRE)–GTx, Inc. (Nasdaq: GTXI) and?Oncternal Therapeutics, Inc., a privately held clinical-stage biotechnology company developing potential first-in-class therapeutic candidates for cancers with critical unmet medical need, today jointly announced?that they have entered into a definitive merger agreement under which the stockholders of Oncternal would become the majority owners of GTx?s outstanding common stock. The proposed merger will create a publicly-t